Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
July, 2026
July 2026
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Heghine Khachatryan: Advances in Targeted Therapy Transforming TTP Management at ASH Highlights 2026
Heghine Khachatryan/LinkedIn
Feb 13, 2026, 12:35

Heghine Khachatryan: Advances in Targeted Therapy Transforming TTP Management at ASH Highlights 2026

Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, shared a post on LinkedIn:

“ASH Highlights 2026 – Advances in Thrombotic Thrombocytopenic Purpura (TTP)

One of the most impactful sessions today focused on emerging therapeutic strategies in immune TTP (iTTP) and congenital TTP (cTTP), particularly CD38-targeted therapy and recombinant ADAMTS13 replacement.

Daratumumab in Immune TTP (iTTP)

Data from the international, multicenter DarTTP study demonstrated:

  • Rapid ADAMTS13 remission in 75% of patients with iTTP who were refractory or intolerant to rituximab and other immunosuppressive therapies
  •  Sustained remission (>6 months) in approximately two-thirds of responders
  •  Targeting CD38+ plasma cells offers a promising strategy in cases where B-cell depletion alone is insufficient

These findings represent an important advancement in the management of refractory iTTP and provide renewed hope for patients at high risk of relapse.

Congenital TTP (cTTP)
The session also highlighted a clinical case discussion and phase 3 data on recombinant ADAMTS13 (rADAMTS13) replacement therapy:

  • Demonstrated favorable efficacy and safety profile
  • Approved in the US, EU, and Japan for both prophylactic and on-demand use
  • Represents a paradigm shift in long-term cTTP management, reducing dependence on plasma infusions

This lecture clearly underscored that TTP treatment is entering a new era of mechanism-based and targeted therapy.

Integrating these advances into national practice remains crucial, particularly with regard to laboratory capacity, ADAMTS13 monitoring, and access to innovative therapeutics in our region.”

Heghine Khachatryan: Advances in Targeted Therapy Transforming TTP Management at ASH Highlights 2026

Find more posts featuring Heghine Khachatryan on Hemostasis Today.

ADAMTS13 CD38-targeted therapy Daratumumab Headlines Hematology Hemostasis Hemostasis News Hemostasis Today Medicine thrombosis Thrombotic Thrombocytopenic Purpura (TTP)
NewsFeed